This guidance has been updated and replaced by NICE technology appraisal guidance on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146).
This guidance has been updated and replaced by NICE technology appraisal guidance on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146).